Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Importance: Hydroxychloroquine, with or without azithromycin, has been considered as a possible therapeutic agent for patients with coronavirus disease 2019 (COVID-19). However, there are limited data on efficacy and associated adverse events. Objective: To describe the association between use of hydroxychloroquine, with or without azithromycin, and clinical outcomes among hospital inpatients diagnosed with COVID-19. Design, Setting, and Participants: Retrospective multicenter cohort study of patients from a random sample of all admitted patients with laboratory-confirmed COVID-19 in 25 hospitals, representing 88.2% of patients with COVID-19 in the New York metropolitan region. Eligible patients were admitted for at least 24 hours between March 15 and 28, 2020. Medications, preexisting conditions, clinical measures on admission, outcomes, and adverse events were abstracted from medical records. The date of final follow-up was April 24, 2020. Exposures: Receipt of both hydroxychloroquine and azithromycin, hydroxychloroquine alone, azithromycin alone, or neither. Main Outcomes and Measures: Primary outcome was in-hospital mortality. Secondary outcomes were cardiac arrest and abnormal electrocardiogram findings (arrhythmia or QT prolongation). Results: Among 1438 hospitalized patients with a diagnosis of COVID-19 (858 [59.7%] male, median age, 63 years), those receiving hydroxychloroquine, azithromycin, or both were more likely than those not receiving either drug to have diabetes, respiratory rate >22/min, abnormal chest imaging findings, O2 saturation lower than 90%, and aspartate aminotransferase greater than 40 U/L. Overall in-hospital mortality was 20.3% (95% CI, 18.2%-22.4%). The probability of death for patients receiving hydroxychloroquine + azithromycin was 189/735 (25.7% [95% CI, 22.3%-28.9%]), hydroxychloroquine alone, 54/271 (19.9% [95% CI, 15.2%-24.7%]), azithromycin alone, 21/211 (10.0% [95% CI, 5.9%-14.0%]), and neither drug, 28/221 (12.7% [95% CI, 8.3%-17.1%]). In adjusted Cox proportional hazards models, compared with patients receiving neither drug, there were no significant differences in mortality for patients receiving hydroxychloroquine + azithromycin (HR, 1.35 [95% CI, 0.76-2.40]), hydroxychloroquine alone (HR, 1.08 [95% CI, 0.63-1.85]), or azithromycin alone (HR, 0.56 [95% CI, 0.26-1.21]). In logistic models, compared with patients receiving neither drug cardiac arrest was significantly more likely in patients receiving hydroxychloroquine + azithromycin (adjusted OR, 2.13 [95% CI, 1.12-4.05]), but not hydroxychloroquine alone (adjusted OR, 1.91 [95% CI, 0.96-3.81]) or azithromycin alone (adjusted OR, 0.64 [95% CI, 0.27-1.56]), . In adjusted logistic regression models, there were no significant differences in the relative likelihood of abnormal electrocardiogram findings. Conclusions and Relevance: Among patients hospitalized in metropolitan New York with COVID-19, treatment with hydroxychloroquine, azithromycin, or both, compared with neither treatment, was not significantly associated with differences in in-hospital mortality. However, the interpretation of these findings may be limited by the observational design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288
RetractedZhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254
A novel coronavirus outbreak of global health concern
Wang, C., Horby, P. W., Hayden, F. G., & Gao, G. F. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30185-9 · Cited by 7,700
Sensitivity analysis in observational research: Introducing the E-value
VanderWeele, T. J., & Ding, P. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2607 · Cited by 6,350
The Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa237 · Cited by 2,662
Garg, S., Kim, L., Whitaker, M., O’Halloran, A., Cummings, C., Holstein, R., Prill, M., Chai, S. J., Kirley, P. D., Alden, N. B., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6915e3 · Cited by 2,335
Self-citationClinical Characteristics of Covid-19 in New York City
Goyal, P., Choi, J. J., Pinheiro, L. C., Schenck, E. J., Chen, R., Jabri, A., Satlin, M. J., Campion, T. R., Nahid, M., Ringel, J. B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2010419 · Cited by 2,234
Liu, J., Cao, R., Xu, M., Wang, X., Zhang, H., Hu, H., Li, Y., Hu, Z., Zhong, W., & Wang, M. (2020) · Cell Discovery · doi:10.1038/s41421-020-0156-0 · Cited by 2,070
Cited by
Characteristics of SARS-CoV-2 and COVID-19
Hu, B., Guo, H., Zhou, P., & Shi, Z.-L. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00459-7 · Cited by 5,291
Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020) · JAMA · doi:10.1001/jama.2020.12839 · Cited by 4,609
COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives
Nishiga, M., Wang, D. W., Han, Y., Lewis, D. B., & Wu, J. C. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0413-9 · Cited by 1,409
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
Boulware, D. R., Pullen, M. F., Bangdiwala, A. S., Pastick, K. A., Lofgren, S. M., Okafor, E. C., Skipper, C. P., Nascene, A. A., Nicol, M. R., Abassi, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2016638 · Cited by 1,318
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
Cavalcanti, A. B., Zampieri, F. G., Rosa, R. G., Azevedo, L. C. P., Veiga, V. C., Avezum, A., Damiani, L. P., Marcadenti, A., Kawano-Dourado, L., Lisboa, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2019014 · Cited by 1,083
Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19
Magagnoli, J., Narendran, S., Pereira, F., Cummings, T. H., Hardin, J. W., Sutton, S. S., & Ambati, J. (2020) · Med · doi:10.1016/j.medj.2020.06.001 · Cited by 656
Artificial intelligence in COVID-19 drug repurposing
Zhou, Y., Wang, F., Tang, J., Nussinov, R., & Cheng, F. (2020) · The Lancet Digital Health · doi:10.1016/s2589-7500(20)30192-8 · Cited by 636
Ethnicity and clinical outcomes in COVID-19: A systematic review and meta-analysis
Sze, S., Pan, D., Nevill, C. R., Gray, L. J., Martin, C. A., Nazareth, J., Minhas, J. S., Divall, P., Khunti, K., Abrams, K. R., et al. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100630 · Cited by 633
Innovative Treatment Strategies to Accelerate Wound Healing: Trajectory and Recent Advancements
Kolimi, P., Narala, S., Nyavanandi, D., Youssef, A. A. A., & Dudhipala, N. (2022) · Cells · doi:10.3390/cells11152439 · Cited by 585
Ehrenfeld, M., Tincani, A., Andreoli, L., Cattalini, M., Greenbaum, A., Kanduc, D., Alijotas-Reig, J., Zinserling, V., Semenova, N., Amital, H., et al. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102597 · Cited by 559
Arshad, S., Kilgore, P., Chaudhry, Z. S., Jacobsen, G., Wang, D. D., Huitsing, K., Brar, I., Alangaden, G. J., Ramesh, M. S., McKinnon, J. E., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.06.099 · Cited by 546
The impact of ethnicity on clinical outcomes in COVID-19: A systematic review
Pan, D., Sze, S., Minhas, J. S., Bangash, M. N., Pareek, N., Divall, P., Williams, C. M., Oggioni, M. R., Squire, I. B., Nellums, L. B., et al. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100404 · Cited by 519
Ortiz-Prado, E., Simbaña-Rivera, K., Gómez- Barreno, L., Rubio-Neira, M., Guaman, L. P., Kyriakidis, N. C., Muslin, C., Jaramillo, A. M. G., Barba-Ostria, C., Cevallos-Robalino, D., et al. (2020) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2020.115094 · Cited by 458
New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis
Hou, Y., Zhao, J., Martin, W., Kallianpur, A., Chung, M. K., Jehi, L., Sharifi, N., Erzurum, S., Eng, C., & Cheng, F. (2020) · BMC Medicine · doi:10.1186/s12916-020-01673-z · Cited by 438
COVID-19 and the elderly: insights into pathogenesis and clinical decision-making
Perrotta, F., Corbi, G., Mazzeo, G., Boccia, M., Aronne, L., D’Agnano, V., Komici, K., Mazzarella, G., Parrella, R., & Bianco, A. (2020) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01631-y · Cited by 420
COVID-19 and cardiac arrhythmias
Bhatla, A., Mayer, M. M., Adusumalli, S., Hyman, M. C., Oh, E., Tierney, A., Moss, J., Chahal, A. A., Anesi, G., Denduluri, S., et al. (2020) · Heart Rhythm · doi:10.1016/j.hrthm.2020.06.016 · Cited by 406
Hilbrands, L. B., Duivenvoorden, R., Vart, P., Franssen, C. F. M., Hemmelder, M. H., Jager, K. J., Kieneker, L. M., Noordzij, M., Pena, M. J., Vries, H. D., et al. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa261 · Cited by 393
COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State
Tesoriero, J. M., Swain, C.-A. E., Pierce, J. L., Zamboni, L., Wu, M., Holtgrave, D. R., Gonzalez, C. J., Udo, T., Morne, J. E., Hart-Malloy, R., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.37069 · Cited by 391
Self-citationCOVID-19: A Multidisciplinary Review
Chams, N., Chams, S., Badran, R., Shams, A., Araji, A., Raad, M., Mukhopadhyay, S., Stroberg, E., Duval, E. J., Barton, L. M., et al. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.00383 · Cited by 386
Furtado, R. H. M., Berwanger, O., Fonseca, H. A., Corrêa, T. D., Ferraz, L. R., Lapa, M. G., Zampieri, F. G., Veiga, V. C., Azevedo, L. C. P., Rosa, R. G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31862-6 · Cited by 360
COVID-19 in early 2021: current status and looking forward
Wang, C., Wang, Z., Wang, G., Lau, J. Y.-N., Zhang, K., & Li, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00527-1 · Cited by 339
Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects
Visca, D., Ong, C. W. M., Tiberi, S., Centis, R., D’Ambrosio, L., Chen, B., Mueller, J., Mueller, P., Duarte, R., Dalcolmo, M., et al. (2021) · Pulmonology · doi:10.1016/j.pulmoe.2020.12.012 · Cited by 328
Fiolet, T., Guihur, A., Rebeaud, M. E., Mulot, M., Peiffer-Smadja, N., & Mahamat-Saleh, Y. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.08.022 · Cited by 306
Special Article - Acute myocardial injury in patients hospitalized with COVID-19 infection: A review
Bavishi, C., Bonow, R. O., Trivedi, V., Abbott, J. D., Messerli, F. H., & Bhatt, D. L. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.05.013 · Cited by 298
Mitjà, O., Corbacho-Monné, M., Ubals, M., Tebé, C., Peñafiel, J., Tobias, A., Ballana, E., Alemany, A., Riera-Martí, N., Pérez, C. A., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1009 · Cited by 290
Rahman, S., Montero, M. T. V., Rowe, K., Kirton, R., & Kunik, F. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1902303 · Cited by 289
Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York
Rosenberg, E. S., Tesoriero, J. M., Rosenthal, E. M., Chung, R., Barranco, M. A., Styer, L. M., Parker, M. M., John Leung, S.-Y., Morne, J. E., Greene, D., et al. (2020) · Annals of Epidemiology · doi:10.1016/j.annepidem.2020.06.004 · Cited by 262
Self-citationLagier, J.-C., Million, M., Gautret, P., Colson, P., Cortaredona, S., Giraud-Gatineau, A., Honoré, S., Gaubert, J.-Y., Fournier, P.-E., Tissot-Dupont, H., et al. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101791 · Cited by 254
Molecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective
Hosoki, K., Chakraborty, A., & Sur, S. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.033 · Cited by 63
Kamran, F., Tang, S., Otles, E., McEvoy, D. S., Saleh, S. N., Gong, J., Li, B. Y., Dutta, S., Liu, X., Medford, R. J., et al. (2022) · BMJ · doi:10.1136/bmj-2021-068576 · Cited by 60
Cegolon, L., Javanbakht, M., & Mastrangelo, G. (2020) · International Journal of Hygiene and Environmental Health · doi:10.1016/j.ijheh.2020.113605 · Cited by 44
(2024) · Journal of Community Medicine & Public Health · doi:10.29011/2577-2228.100460 · Cited by 19
Insights in Chloroquine Action: Perspectives and Implications in Malaria and COVID‐19
Pillat, M. M., Krüger, A., Guimarães, L. M. F., Lameu, C., de Souza, E. E., Wrenger, C., & Ulrich, H. (2020) · Cytometry Part A · doi:10.1002/cyto.a.24190 · Cited by 17
Metadata
- Authors
- Rosenberg, E. S., Dufort, E. M., Udo, T., Wilberschied, L. A., Kumar, J., Tesoriero, J., Weinberg, P., Kirkwood, J., Muse, A., DeHovitz, J., Blog, D. S., Hutton, B., Holtgrave, D. R., & Zucker, H. A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2020-06-23
- Volume
- 323
- Issue
- 24
- Pages
- 2493
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W3023082818
- Cited by
- 1,156
- References
- 22
- FWCI
- 33.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.